EXDENSUR Solution for injection Ref.[116332] Active ingredients: Depemokimab

Source: European Medicines Agency (EU)  Revision Year: 2026  Publisher: GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, D24 YK11, Ireland

Product name and form

EXDENSUR 100 mg solution for injection in pre-filled pen.

EXDENSUR 100 mg solution for injection in pre-filled syringe.

Pharmaceutical Form

Solution for injection (injection).

Colourless, yellow to brown, clear to opalescent solution, with a pH of 6.0 and an osmolality of 350 mOsm/kg.

Qualitative and quantitative composition

Each mL of solution for injection contains 100 mg of depemokimab.

Depemokimab is a recombinant humanised (IgG1, kappa) monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipients with known effect:

Each mL of solution for injection contains 0.2 mg polysorbate 80.

For the full list of excipients, see section 6.1.

Active Ingredient

Depemokimab targets human IL-5 with a binding affinity of 10.5 pM, thereby blocking the binding to the IL-5 receptor alpha expressed on the cell surface with picomolar potency (IC50 4 pM) in vitro. IL-5 is a pleiotropic cytokine with established impact on eosinophils and other immune and structural cells. In severe asthma, inhibition of IL-5 has demonstrated an improvement in epithelial integrity, mucus plugging and reduction in tissue remodelling. However, the mechanism of action has not been definitively established.

List of Excipients

Histidine
Histidine monohydrochloride
Trehalose dihydrate
Arginine hydrochloride
Disodium edetate
Polysorbate 80 (E433)
Water for injections

Pack sizes and marketing

EXDENSUR 100 mg solution for injection in pre-filled pen:

1 mL solution in a Type 1 glass syringe with a fixed needle (stainless steel) in a pre-filled pen.

Pack size: 1 pre-filled pen.

EXDENSUR 100 mg solution for injection in pre-filled syringe:

1 mL solution in a Type 1 glass syringe with a fixed needle (stainless steel) and passive safety needle guard.

Pack size: 1 pre-filled syringe.

Marketing authorization holder

GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, D24 YK11, Ireland

Marketing authorization dates and numbers

EXDENSUR 100 mg solution for injection in pre-filled pen: EU/1/25/2007/001

EXDENSUR 100 mg solution for injection in pre-filled syringe: EU/1/25/2007/002

Drugs

Drug Countries
EXDENSUR Estonia, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.